(Reuters) -The European Union’s medicines regulator on Friday granted a conditional authorisation for Madrigal Pharmaceuticals’ drug for a type of fatty liver disease, paving the way to make it the first treatment available for the condition in the region.
The drug, sold as Rezdiffra, was first approved in the United States in March last year.
The disease known as non-alcoholic steatohepatitis (NASH), or more recently renamed as metabolic dysfunction-associated steatohepatitis (MASH), causes excess build up of fat in the liver, resulting in inflammation and fibrosis, or scarring, of the organ.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
Comments